Physician profile
Tarek Eldawy
NPI 1669416459
$49,425.61
in general payments reported to CMS, 2019-2025
73 companies · $8,167 in 2025
The $8,167 reported for 2025 was more than what 79% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $3,148 · 2021: $295 · 2022: $4,843 · 2023: $7,802 · 2024: $8,653 · 2025: $8,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $6,488 · Long Term Medical Supply Or Device Loan: $2,097 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,070 · Travel and Lodging: $923 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,827.88 |
| Consulting Fee | $6,487.50 |
| Long Term Medical Supply Or Device Loan | $2,096.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,070.00 |
| Travel and Lodging | $923.41 |
| Education | $216.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15,888.64 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Pfizer INC. | $4,858.46 | 2019-2025 | |
| Abbvie INC. | $4,354.96 | 2019-2025 | |
| Lilly USA, LLC | $3,969.17 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $3,154.73 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $2,451.89 | 2024-2025 | Tazverik, Somatuline Depot, Onivyde |
| E.R. Squibb & Sons, L.L.C. | $2,109.28 | 2019-2025 | Opdivo, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $1,792.93 | 2019-2025 | |
| Celgene Corporation | $927.15 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Merck Sharp & Dohme LLC | $789.34 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $623.85 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $592.80 | 2022-2025 | Rybrevant, Erleada, Akeega |
| Eisai INC. | $506.22 | 2021-2025 | |
| Daiichi Sankyo INC. | $476.00 | 2022-2025 | Enhertu, Vanflyta, Datroway |
| Adc Therapeutics America, INC. | $391.15 | 2024-2025 |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $358.00 | 2019-2025 | Ultomiris, Soliris |
| Sobi, INC | $344.15 | 2023-2025 | |
| Genentech USA, INC. | $334.57 | 2019-2025 | Tecentriq, Venclexta, Phesgo |
| Genzyme Corporation | $330.96 | 2023-2025 | |
| Gilead Sciences, INC. | $327.54 | 2021-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $325.78 | 2024-2025 | Besremi |
| Amgen INC. | $282.26 | 2019-2025 | Blincyto, Kyprolis |
| Puma Biotechnology, INC. | $254.81 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $252.31 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Stemline Therapeutics INC. | $217.27 | 2023-2024 | Orserdu |
| Glaxosmithkline, LLC. | $213.10 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $183.12 | 2022-2025 | Libtayo |
| Seagen INC. | $168.27 | 2022-2025 | Adcetris, Tivdak |
| Astellas Pharma US INC | $146.97 | 2023-2025 | Vyloy, Padcev, Xtandi |
| Myovant Sciences INC. | $143.93 | 2021-2022 | |
| Blueprint Medicines Corporation | $139.02 | 2023-2025 | Ayvakit |
| Array Biopharma INC | $117.97 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Servier Pharmaceuticals LLC | $114.06 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $110.58 | 2024-2025 | Xpovio |
| Kite Pharma, INC. | $108.89 | 2023-2025 | Yescarta |
| Boston Scientific Corporation | $107.58 | 2022 | |
| Pharmacosmos Therapeutics INC. | $106.87 | 2023-2025 | Monoferric, Cosela |
| Jazz Pharmaceuticals INC. | $102.30 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $101.97 | 2019 | |
| Tersera Therapeutics LLC | $101.09 | 2024-2025 | Zoladex |
| Emd Serono, INC. | $89.36 | 2022-2025 | Bavencio |
| Dendreon Pharmaceuticals LLC | $85.78 | 2024-2025 | Provenge |
| Agios Pharmaceuticals, INC. | $84.37 | 2023-2025 | Pyrukynd |
| Fennec Pharmaceuticals, INC. | $82.37 | 2024-2025 | Fyarro, Pedmark |
| Genmab U.S., INC. | $81.49 | 2024 | Epkinly |
| Springworks Therapeutics, INC. | $65.24 | 2024-2025 | Ogsiveo |
| Syndax Pharmaceuticals, INC. | $64.59 | 2025 | |
| Epizyme, INC. | $64.32 | 2021-2022 | |
| Menarini Silicon Biosystems, INC. | $62.40 | 2024-2025 | |
| Beigene USA, INC. | $60.01 | 2024 | Brukinsa |
| Novocure INC. | $59.87 | 2025 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.16 | 2025 | |
| Tempus Ai, INC | $47.51 | 2024-2025 | Xt Cdx |
| G1 Therapeutics, INC. | $46.26 | 2023 | Cosela |
| Kyowa Kirin, INC. | $45.45 | 2024-2025 | Poteligeo |
| Mirati Therapeutics, INC. | $42.64 | 2024 | Krazati |
| Adaptive Biotechnologies Corporation | $42.46 | 2022-2025 | Clonoseq |
| Exelixis INC. | $42.04 | 2024-2025 | Cabometyx |
| Beone Medicines USA, INC. | $41.56 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $40.67 | 2024 | Tavalisse, Rezlidhia |
| Deciphera Pharmaceuticals INC. | $38.68 | 2023-2025 | Qinlock, Romvimza |
| Janssen Pharmaceuticals, INC | $32.67 | 2019-2024 | Xarelto |
| Octapharma USA, INC. | $32.57 | 2023 | Panzyga, Cutaquig |
| Immunocore Limited | $31.74 | 2025 | Kimmtrak |
| Corcept Therapeutics | $28.35 | 2025 | Korlym |
| Amneal Pharmaceuticals LLC | $26.31 | 2025 | Alymsys |
| Sirtex Medical INC | $26.03 | 2019 | |
| Foundation Medicine, INC. | $25.97 | 2023 | |
| Geron Corporation | $23.39 | 2025 | Rytelo |
| Taiho Oncology, INC. | $22.70 | 2023 | |
| Morphosys, US INC. | $19.51 | 2023 | Monjuvi |
| Coherus Oncology, INC. | $18.50 | 2025 | Loqtorzi |
| Recordati_rare_diseases_inc. | $17.70 | 2025 | Enjaymo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarek Eldawy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.